Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 2/20 | 0.48 |
| ▸ | CKS1B | P61024 | 2/20 | 0.46 |
| ▸ | SKP1 | P63208 | 2/20 | 0.46 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.45 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 2/20 | 0.42 |
| ▸ | BACE1 | P56817 | 4/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | KIT | P10721 | 1/20 | 0.42 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.41 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.41 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL430227 | 0.84 | CYP2C9 (0.52) | GBA1CKS1BSKP1SKP2GPR119 | |
| SCHEMBL425806 | 0.83 | BACE1 (0.51) | GBA1CKS1BSKP1SKP2GPR119 | |
| SCHEMBL5379011 | 0.82 | GBA1 (0.49) | GBA1CKS1BSKP1SKP2GPR119 | |
| SCHEMBL431774 | 0.81 | GBA1 (0.48) | GBA1CKS1BSKP1SKP2GPR119 | |
| SCHEMBL429714 | 0.81 | GBA1 (0.48) | GBA1CKS1BSKP1SKP2GPR119 | |
| SCHEMBL428233 | 0.81 | GBA1 (0.48) | GBA1CKS1BSKP1SKP2GPR119 | |
| SCHEMBL23360356 | 0.81 | GPR119 (0.53) | GPR119 | |
| SCHEMBL428076 | 0.80 | GBA1 (0.48) | GBA1CKS1BSKP1SKP2GPR119 | |
| SCHEMBL430252 | 0.80 | GBA1 (0.48) | GBA1CKS1BSKP1SKP2GPR119 | |
| SCHEMBL4176341 | 0.80 | CKS1B (0.53) | GBA1CKS1BSKP1SKP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022056-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | BENTLEY JONATHAN (IT) | 2012-01-26 | — | — | US | disclosed |
| US-20120022056-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | BENTLEY JONATHAN (IT) | 2012-01-26 | — | — | US | disclosed |
| US-20120022056-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | BENTLEY JONATHAN (IT) | 2012-01-26 | — | — | US | disclosed |
| EP-1786822-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006024517-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022056-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | GABBR1, GABRQ, GABRE | GBA1 192/4885CKS1B 1412/4885SKP1 2162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.